Background: Although, especially in the United States, there has been a recent surge of legalized cannabis for either recreational or medicinal purposes, surprisingly little is known about clinical doseresponse relationships, pharmacodynamic and toxicodynamic effects of cannabinoids such as D9-tetrahydrocannabinol (THC). Even less is known about other active cannabinoids.
INTRODUCTION
Cannabis is by far the most widely cultivated, distributed, and abused drug. 1 Approximately 147 million people, 2.5% of the world population, consume Cannabis annually compared with 0.2% consuming cocaine and 0.2% consuming opiates. 1 The major psychoactive constituent in Cannabis is Δ 9 -tetrahydrocannabinol (THC). Compounds that are structurally similar to THC are referred to as cannabinoids. In addition, a number of recently identified compounds that differ structurally from cannabinoids but share many of their pharmacological properties are also called cannabinoids. 1 Cannabinoids are biologically active compounds that exhibit drug-like effects throughout the body, especially in the central nervous system and immune system. 2 As of January 2017, 28 US states have passed laws that allow use of marijuana for medical purposes, with 8 states also allowing recreational use. 3 Nevertheless, the use of marijuana is associated with health risks. [4] [5] [6] [7] [8] Human clinical trials have mostly focused on the effects of medical marijuana mediated by THC without significant benefit. It has been shown that certain cannabinoids may modulate the effects of other cannabinoids (e.g., CBDs modulates THC's effects) and that some cannabinoids may inherently be more harmful than others. 9, 10 To date, most studies assessing the positive and negative effects of Cannabis use have been performed either in a controlled research environment or epidemiological studies in an environment in which marijuana use was restricted and illegal. 4 Most of these studies also failed to convincingly establish cause-effect relationships. [4] [5] [6] [7] [8] 11 Hence, substantial scientific and public uncertainty exists regarding the behavioral and physical effects of marijuana use, especially with a wide range of routes and modes of administration including, but not limited to, smoking, vaporization, and edibles. Moreover, some of these commercially available forms of marijuana may have substantially higher contents of THC than has previously been studied. 12 Furthermore, other cannabinoids are present in these formulations, depending on the marijuana strain, cultivation conditions, plant maturity, and processing procedures. 13 Individuals also use enriched preparations such as oils, concentrates for vaporizers or "dabs." 14 Chemically, cannabinoids were defined as a group of C21 terpenophenolic compounds uniquely produced by Cannabis. 15 Later, the development of synthetic cannabinoids (e. g., HU-210) changed this definition, as has the discovery of endogenous cannabinoids (e.g., anandamide), defined as "endocannabinoids" by Fontana et al. 16 Thus, the term "phytocannabinoids" was created to designate the compounds produced by Cannabis. To this date, there are over 600 known plant constituents in Cannabis including 104 cannabinoids and 200 terpenes. 17 The phytocannabinoids are separated into subclasses including, but not limited to, tetrahydrocannabinols (THC), cannabinols (CBNs), cannabidiols (CBD), cannabigerols (CBG), cannabivarins [e.g., D9-tetrahydrocannabivarin (THCV)], cannabichromenes (CBCs), and other miscellaneous types. After THC, CBD is the second most abundant cannabinoid in marijuana and the most abundant in hemp plants. 14 Recent investigations have shown that other less investigated cannabinoids such as CBD, CBC, CBN, and THCV may have therapeutic benefits in the treatment of various conditions, including chronic pain, anxiety, posttraumatic stress disorder, rheumatoid arthritis, schizophrenia, diabetes, cardiovascular disease, nausea, cancer, and other conditions. [18] [19] [20] [21] [22] [23] [24] [25] [26] Currently, most bioanalytical assays that measure cannabinoids are limited to THC and its metabolites, [27] [28] [29] [30] [31] [32] [33] [34] [35] with only a few including other cannabinoids. 36 However, with the recent wave of marijuana legalization and the use of other cannabinoids such as CBD in preclinical, clinical, and observational trials, sensitive and specific analytical assays are needed to establish dose-effect relationships of THC and other cannabinoids.
To address this gap, we have established and validated a cannabinoid liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) assay with online trapping. This assay quantifies 11 cannabinoids and their metabolites for which appropriate reference materials are currently commercially available [THC, 11-hydroxy-D9-tetrahydrocannabinol (11OH-THC), 11-nor-D9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH), THC-C-gluc, CBD, CBN, CBG, CBC, CBDV, THCV, and THCV-COOH] in human urine and plasma. This automated, specific, and fast assay with high sensitivity involves a simple 1-step sample preparation procedure and is currently used for pharmacokinetic monitoring of several ongoing clinical and observational studies.
MATERIALS AND METHODS

Chemicals
The analytes and internal standards were purchased from the following sources: THC, 11OH-THC, 11-nor-D9-tetrahydrocannabinol-9-carboxylic acid glucuronide (THC-C-gluc), CBN, and cannabidivarin (CBDV) were purchased from Cerilliant (Corporation, Round Rock, TX). CBD, CBC, CBG, and THCV were purchased from Cayman Chemicals (Ann Arbor, MI). THC-COOH and 11-nor-9-carboxy-D9-tetrahydrocannabivarin (THCV-COOH) were purchased from Elsohly Laboratories (Oxford, MS).
The deuterated internal standard compounds D9-tetrahydrocannabinol-d3
(THC-d3), 11-hydroxy-D9-tetrahydrocannabinol-d3 (11OH-THC-d3), cannabinol-d3 (CBN-d3), and cannabidiol-d3 (CBD-d3) were purchased from Cerilliant. The deuterated internal standard 11-nor-D9-tetrahydrocannabinol-9-carboxylic acid-d6 (THC-COOH-d6) was purchased from Elsohly Laboratories.
The chemicals and solvents used for this study including methanol, isopropanol, acetonitrile, water, formic acid (all LC/MS grade), and zinc sulfate (ZnSO 4 ) were purchased from Fisher Scientific (Waltham, MA).
Working Range
The calibrator and quality control (QC) sample preparation was identical for both urine and plasma. Calibration curves were prepared by spiking 20 mL of 10· stock solution containing all analytes into 180 mL of blank matrix and resulting in final concentrations of 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25, 50, 100, 200, and 400 ng/mL for all analytes except for THC-C-gluc, which was 5-fold higher concentrated to cover its higher urine concentration range. Because this assay measures 11 analytes with different working ranges, it was necessary to analyze a rather large set of QCs including 1, 2, 4, 8, 16, 128, and 320 ng/mL (as aforementioned, THC-C-gluc concentrations were 5-fold higher).
Sample Extraction
The sample extraction procedure was identical for both matrices. Ten microliters of 20-fold aliquots of 200 mL of the calibrator, QC, or blank sample (urine or plasma) were transferred into a 1.5-mL low-binding polypropylene vial (Sarstedt, Nümbrecht, Germany). Eight hundred microliters of 0.2 mol/L ZnSO 4 30% water/70% methanol (v/v) containing the internal standards (5 ng/mL) were added. Samples were vortexed for 10 minutes and then centrifuged (at 27,500g, 48C, 10 minutes, Sorvall Legend 23R or Thermo Scientific MR 23i). The supernatant was transferred into a high-performance liquid chromatography (HPLC) autosampler vial. Figure S1 , http://links.lww.com/TDM/ A190 in Supplemental Digital Content 1. Two hundred fifty microliters of the samples were injected onto a 4.6-· 12.5-mm online extraction column (Zorbax XDB C8, Agilent Technologies) with a particle size of 5 mm. Samples were loaded and washed with a mobile phase of 45% methanol supplemented with 0.1% formic acid and 55% 0.1% formic acid in water. The flow was increased from 0.5 to 1.5 mL/min within 1 minute. The extraction column was kept at room temperature. After 1 minute, the switching valve was activated, and the analytes were eluted in the back-flush mode from the extraction column onto a 4.6 · 50 mm Poroshell Eclipse C18, 2.7 mm analytical column (Agilent Technologies). The analytical column was kept at 608C. The organic solvent (mobile phase B) consisted of 20% isopropanol, 20% methanol, and 60% acetonitrile, and the aqueous solvent (mobile phase A) consisted of water supplemented with 0.1% formic acid. The analytical gradient started with a flow rate of 0.75 mL/min and 60% of solvent B for the first minute. Within the following 3 minutes, the flow rate and the organic solvent content were increased to 1 mL/min and 95% solvent B, respectively. From 4 to 6 minutes, the solvent B was increased to 100%. At 6.2 minutes, the system returned to starting conditions for 1.8 minutes to equilibrate before the following injection. The HPLC system was interfaced with an ABSciex API5000 tandem mass spectrometer (Sciex, Concord, ON, Canada) using a turbo V ion source operated in the positive atmospheric pressure chemical ionization (APCI) mode. The nebulizer current was set to 5 mA; the source gases 1 and 2 were set to 40 (arbitrary units); the source temperature was set to 4508C; the entrance potential and the collision cell exit potential were set to 10 and 11 V, respectively. A complete list of multiple reaction monitoring (MRM) transitions and parameters used in this study is shown in Table S1 , Supplemental Digital Content 2, http:// links.lww.com/TDM/A191; the MRM transitions used for the quantification and the corresponding deuterated internal standards are listed in Table S1 , Supplemental Digital Content 2, http://links.lww.com/TDM/A191.
Validation Strategy
The assay was developed and validated in human urine and plasma. The recoveries and matrix effects (ion suppression/ ion enhancement) were determined as described by Matuszewski et al. 12 In addition, matrix effects were also studied by postcolumn infusion experiments as described by Mueller et al. 37 Recovery and matrix effect testing were based on blank plasma and urine samples collected from 6 different individuals. For the specificity and selectivity of the assay, we showed that there was no endogenous signal interference within the extracted blank sample of each individual lot used [blank signal needed to be ,20% of the lower limit of quantification (LLOQ)].
The determination of the LLOQ and range of reliable response was performed by analysis of 6 sets (n = 6) of calibration curves. The requirement for the LLOQ was a minimum mean accuracy between 80% and 120%, and the percentage of relative standard deviation had to be # 20%. The correlation coefficient (r) was required to be . 0.99, and at least two-thirds of the back-calculated concentrations had to be within 85%-115% of the nominal concentration (80%-120% for the lowest calibrator). Intrabatch accuracy, interbatch accuracy, intrabatch imprecision, and interbatch imprecision were determined based on the analysis of QC samples over 3 days. Each day, a set of 6 QCs was analyzed per QC level (n = 6). For this, 2 calibration curves were generated: one was analyzed at the beginning and one at the end of the analytical batch. The results were acceptable if the percentage of relative standard deviation was #15% and accuracy was within 85%-115% of the expected concentration. The determination of dilution integrity was based on samples enriched above the upper limit of quantification (ULOQ), which had been diluted, and results had to be within 85%-115% of the nominal concentration. Carryover was excluded by analysis of blank buffer samples following the highest calibrator and QC samples. Signals had to be # 20% of the LLOQ.
Stock solution stability was assessed by analysis of a buffer stock solution at 200 ng/mL that was stored at 2208C for the duration of 1 week or 1 month. Autosampler stability was assessed by analyzing sets of extracted QC samples after 24 and 48 hours of storage in the autosampler at +48C. These QCs were analyzed together with freshly prepared calibrator samples. Freeze-thaw cycle stability was assessed by exposing sets of QCs to 1, 2, and 3 freeze-thaw cycles (2808C) followed by analysis using freshly prepared calibration curves. Short-term stability was assessed by storing QC samples at room temperature (benchtop) and 48C (refrigerator) for 2 hours, 4 hours, 1 day, and 1 week before analysis. Sample stability was also tested by storing QC samples at 220 and 2808C for the duration of 1 week, 1 month, and 4 months before analysis. Stability was assumed if the concentrations of the stored test samples were within 85%-115% of the reference concentrations.
Proof of Concept in Samples From Clinical and Observational Marijuana Studies
The assay was used to analyze plasma and urine samples that were collected as part of various clinical and observational trials investigating the effects of medical marijuana in the context of various conditions such as inflammatory bowel disease, Parkinson disease, pediatric epilepsy, pediatric patients with brain tumors, and changes in sleep patterns. All human plasma and urine samples were collected as part of Colorado Department of Public Health and Environment (CDPHE)-funded medical marijuana grants (a complete list of studies is available in Ref. 38 ). All studies were reviewed and approved by the Colorado Multiple Institutional Review Board (COM-IRB, Aurora, CO). Informed written assent/consent, as appropriate, was obtained from all study participants.
RESULTS
Assay Development
Initially, chromatographic conditions were optimized, including the testing of various HPLC columns, mobile phases, and gradients. The best separation of isobaric cannabinoids or cannabinoid metabolites that fragmented in source (e.g., CBD, THC, CBC, and THC-C-gluc) was achieved with the assay described in the Methods section. Representative extracted ion chromatograms for the 11 cannabinoids are shown in Figure 1 .
During assay development, carryover was an issue at first. Thus, extraction column breakthrough experiments were performed. For this, the organic solvent concentration used for the sample load onto the extraction column was systematically increased until a peak broadening or disappearance (breakthrough) was observed. This was the case at organic solvent concentrations of more than 55% during sample loading (please see Figure S2 , Supplemental Digital Content 1, http://links. lww.com/TDM/A190, top row, right ion chromatogram). THC-C-gluc was among the most polar compounds included in this assay, and the disappearance of THC-C-gluc was observed using 70% organic solvent during sample loading (for details, please see Figure S2 , Supplemental Digital Content 1, http:// links.lww.com/TDM/A190). However, enhanced carryover was observed when organic solvent concentrations were lower than 30% during sample loading (see Figure S2 , Supplemental Digital Content 1, http://links.lww.com/TDM/A190 bottom, left ion chromatogram). Thus, the optimal mobile phase composition during sample loading was determined to be 45% organic and 55% of aqueous solvent.
To detect ionization efficiency changes attributable to coeluting matrix substances, we tested urine and plasma collected from 6 different individuals similar to that described by Mueller et al 37 in both electrospray ionization (ESI) and APCI modes. After protein precipitation, samples were enriched and back flushed onto the analytical column, as described above. We infused cannabinoids (10 mg/L dissolved in methanol) postcolumn through a T-piece at 1 mL/ h using a syringe pump (Harvard Apparatus, Holliston, MA). The extent of ion suppression was established by monitoring the intensity of the ion currents in MRM mode at the retention times of analytes and IS. Figure S3A , http://links.lww.com/ TDM/A190, shows a representative ion chromatogram of a plasma extract injected in ESI mode and APCI mode. Substantial ion suppression in the region of the eluting cannabinoids was observed in ESI mode, whereas there was no significant ion suppression observed in any of the analyzed plasma extracts in APCI mode. Ion suppression in ESI mode in extracted urine samples was less pronounced, but still noticeably present (see Figure S3B) . Postcolumn infusion revealed a more stable signal in APCI mode for extracted urine samples as well. To detect if the ion suppression was caused by phosphatidylcholine (PC) species, plasma samples were extracted using the standard extraction protocol and analyzed using the same chromatographic conditions described in the Methods section. The mass spectrometer settings for the detection of PCs described by Little et al 39 were applied. Figure S3C shows that the elution times of PC species were aligned with periods of high ion suppression.
Validation Results
The responses at the retention times of the 11 cannabinoids in the ion chromatograms of extracted blank human EDTA plasma and urine sample matrix (n = 6) were less than 20% of the detector response of that of the lowest calibrators or its internal standards. Thus, the assay was considered specific for the quantification of 11 cannabinoids in human urine and EDTA plasma.
Matrix effect was evaluated by analysis of extracted blank plasma samples and extracted blank urine samples from 6 individuals during constant infusion of the 11 compounds. In APCI mode, no significant matrix effects were observed ( Figure  S3 ). The matrix effect was evaluated by comparing blank extracted matrix samples that had been enriched after extraction with enriched buffer samples as described by Matuszewski et al. 12 This evaluation was performed at 3 different concentrations within the working range of the assay. The matrix effect (as described above) was calculated as follows: %-Matrix Effect = (Area buffer /Area enriched matrix · 100) 2 100.
The mean absolute matrix effects in plasma were determined to be 7.9%, 217.0%, 212.6%, 26.3%, 214.1%, 23.6%, 26.0%, 214.2%, 21.7%, 214.9%, and 22.9%, and the mean matrix effects in urine were 2.4%, 24.6%, 22.6%, 24.2%, 23.3%, 24.3%, 24.5%, 23.4%, 0.2%, 4.3%, and 11.7% for 11OH-THC, CBN, CBG, THC, THCV, THC-COOH, THCV-COOH, CBD, CBC, CBDV, and for THC-C-gluc, respectively. Table 1 shows representative ion chromatograms of blanks and samples at the LLOQ for the cannabinoids based on the acceptance criteria as set forth by the FDA guidance for bioanalytical method development. 40 Determination of the intrabatch and interbatch accuracies and imprecisions was performed on 3 validation days for each matrix. On each validation day, 2 calibration curves of enriched matrix were analyzed with each analytical batch and the correlation coefficient was larger than r = 0.99 for all analytes during all days. Consistently, the accuracy of at least two-thirds of calibration samples (= 66.7%) was between 85% and 115% from nominal (except for the calibrators at the LLOQ, which had to be within 80%-120%). The calibration samples at the LLOQ always showed a signal-to-noise ratio of more than 5:1; no significant interference was present in blank samples, and no significant carryover (less than 1%) was observed. Tables 2  and 3 summarize the key assay performance parameters determined during the validation based on QC samples (n = 6 per level per batch) for plasma and urine. At least twothirds of the QC samples in an analytical batch had to be within 615% of the nominal concentration, and the imprecision had to be less than 15%. Tables 2 and 3 show that these criteria were met for all compounds in both matrices except the cannabivarins THCV and CBDV in plasma and THCV in urine, which would require broader acceptance criteria of 625%.
Dilution integrity was evaluated by enrichment of samples with concentrations 5-fold higher than the ULOQ. These samples were diluted 1/5, 1/10, and 1/20 using blank matrix to fit within the working range of the assay. The accuracies of the diluted samples were within 85%-115% for all compounds except for the cannabivarins (THCV, THCV-COOH, CBDV, and THC-C-gluc) in plasma. The mean accuracies for the cannabinoids in diluted plasma were 113.5%, 113.3%, 110.8%, 111.5%, 122.3%, 109.1%, 120.2%, 112.2%, 104.1%, 123.8%, and 117.5% for 11OH-THC, CBN, CBG, THC, THCV, THC-COOH, THCV-COOH, CBD, CBC, CBDV, and for THC-C-gluc, respectively. For urine, dilution integrity testing failed for most compounds. The back-calculated accuracies in urine were mostly low with 60%-80% for all analytes, except for the cannabivarins THCV-COOH and CBDV, which passed the acceptance criteria of 615% of the nominal value. There was no impact on the stability of cannabinoids observed in either plasma or urine when samples were exposed to up to 3 freeze-thaw cycles (please see Table  S3 , Supplemental Digital Content 2, http://links.lww.com/ TDM/A191). Furthermore, extracted plasma and urine samples were stable in the autosampler at +48C for up to 48 hours. Cannabinoids in plasma and urine were stable at ambient temperature (benchtop) for up to 24 hours except for CBC, which was only stable for up to 4 hours. All cannabinoids were stable for at least 1 week at +48C, 2208C, and 2808C (Table S4 , Supplemental Digital Content 2, http:// links.lww.com/TDM/A191). Most cannabinoids did not pass the acceptance criteria when extracted after storage for extended periods at 2208C and 2808C (please see Table S5 , Supplemental Digital Content 2, http://links.lww.com/ TDM/A191.
Proof of Concept in Samples From Clinical and Observational Marijuana Studies
A total of 352 plasma samples and 93 urine samples were analyzed using the present assay in the time between March 2016 and January 2017 in support of medical marijuana studies (Table 4) . One hundred and twenty-five plasma and 12 urine samples were negative/free of all cannabinoids. Highest concentrations of any cannabinoid detected in both plasma and urine were for 11-Nor-D 9 -THC-9-carboxylic acid glucuronide (THC-C-gluc) with maximum concentrations of 1485 and 7431 ng/mL for plasma and urine, respectively. Most of the clinical studies were observational clinical trials during which study participants consumed For the LLOQ, the accuracy had to be within 80%-120% with less than 20% imprecision and the signal had to be at least 5-fold higher than that of a blank sample. Recovery was determined in samples collected from 6 different individuals at 3 different levels for each analyte. Means 6 standard deviations (SD) are shown. The key assay performance parameters in plasma and urine. Accuracy and imprecision (%CV) were determined over 3 days with 6 sets of QC samples analyzed on each consecutive day. Data listed were based on the QCs within the working range of the assay. Cannabis at home, and samples were collected later at the study sites. Thus, cannabinoid metabolites such as 11OH-THC, THC-COOH, THC-C-gluc, and THCV-COOH were more frequently detected and at higher concentrations than their corresponding cannabinoid precursors (Table 4) . Representative ion chromatograms of plasma samples with high cannabinoid concentrations (A and C) compared with negative samples (B and D) are shown in Figure S4 , Supplemental Digital Content 1, http://links.lww.com/TDM/A190. CBD was detected in a total of 154 of 352 plasma samples with concentrations as high as 344 ng/mL. The highest THC concentration detected in plasma was 256 ng/ mL. In comparison to plasma, only a small number of urine samples contained CBD and/or THC. As expected, 36 THC metabolites were highly abundant in the urine samples. Although reference materials for the major THC metabolites are commercially available and these could be identified in urine, this was not the case for CBD metabolites. Representative ion chromatograms of urine samples after consumption of THC and CBD are shown in Figure S5 Other cannabinoids such as CBC, CBN, CBG, and cannabivarins were only sporadically detectable, mainly in plasma samples with high THC levels, indicating that marijuana had been consumed shortly before the study visit. Except for CBC, these cannabinoids were detected in a small number of samples: CBN in 0.3% of the tested plasma samples, CBG in 2.0%, THCV in 1.4%, and CBDV in 0.3%. However, CBC was detected in 60 plasma samples (17.0% of all samples tested). Forty-three of these samples also contained CBD in combination with CBC and were mostly from patients who had consumed CBD oils.
DISCUSSION
The current standard approach to objectively confirm marijuana use, urine toxicology testing, is usually limited to THC and metabolites, and it does not necessarily reflect systemic exposure. Standard toxicology testing is more qualitative than quantitative, normalization to compensate for different concentrations of urine samples remains a problem, and standard urine toxicology testing does not usually detect exposure to other cannabinoids such as CBD. However, these other cannabinoids are increasingly of clinical importance. In comparison with THC, CBD has several opposing effects on human brain and behavior and modulates THC's effects. 7, 41, 42 THC and CBD are just 2 of 100+ cannabinoids that may mitigate or exacerbate the therapeutic and harmful effects of marijuana, 17 and it is reasonable to expect that cannabinoid profiles in plasma will be of value for the clinical effect/risk assessment of individual patients rather than simply confirming the absence or presence of THC.
In this context, we successfully developed and validated an assay platform that enables monitoring the levels of all major cannabinoids and their metabolites for which, as of today, reference materials are commercially available in human plasma and urine. As described above, we observed extensive ion suppression in plasma samples when ESI was used. Moreover, the chromatographic regions, in which ion suppression was most abundant, were associated with regions in which PC species eluted. Because a complete chromatographic separation of all 11 cannabinoids from these coeluting PC species was not possible without an excessively long gradient, APCI mode was chosen for this assay. The use of APCI substantially reduced ion suppression and allowed for an LC-MS/MS run time of 8 minutes. After the optimization of sample loading conditions, no carryover was detected for most study compounds, except for the most lipophilic compounds THC and CBC, for which it was less than 1%. The LLOQs for most cannabinoids in both matrices were below 1 ng/mL. These limits could only be reached using an online extraction procedure. Published assays with sub ng/mL LLOQs usually use offline solid phase extraction procedures followed by evaporation and reconstitution of analytes before LC-MS analysis 28, 35, [43] [44] [45] [46] or organic extraction followed by evaporation. 47 These procedures are laborious, and evaporation-reconstitution steps are potentially problematic especially for lipophilic cannabinoids because of instability, binding to vessel walls, and poor recovery during reconstitution. Our assay is simple and sensitive enough because peak concentrations of THC after smoking were observed to be 250 ng/mL in plasma, 9,48-50 and 4-hour values were in the range of approximately 2 ng/mL. 9, 48, 50 Dilution integrity testing showed that samples with high cannabinoid concentrations (above the ULOQ) could be diluted in plasma to result in concentrations that are within the working range of the assay. For urine, however, dilution of samples above the ULOQ resulted in backcalculated accuracies that were mostly low and ranged between 60%-80%. This could be explained by the very lipophilic nature of cannabinoids. Enrichment of urine samples at very high cannabinoid concentrations can cause precipitation or binding to the container wall. This could differ among different lots of urine, depending on the urine salt concentration and composition that is highly variable. Thus, urine values above the ULOQ can only be semiquantitatively estimated.
Although the cannabivarins (THCV, CBDV, and THCV-COOH) are structurally closely related to the corresponding cannabinoids (THC, CBD, and THC-COOH), it seemed that the chemical properties differed vastly in contrast to the other cannabinoids included in this assay. As a result, THCV and CBDV were the only compounds that failed the predefined acceptance criteria during assay validation, and broader acceptance criteria may be required.
Cannabinoids were stable at the conditions tested for up to 3 freeze-thaw cycles, 48 hours in the autosampler at +48C, and for up to 1 week at +48C, 2208C, and 2808C in plasma and urine. Urine samples were generally stable when stored for up to 4 months under these conditions with the exceptions of CBG and CBC, which showed a decline of 16%-20% after 4 months of storage. Plasma samples that were stored at 2208C and 2808C for 1 and 4 months, respectively, did not pass the acceptance criteria. Although storage at 2808C for the first month shows a decline of approximately 20% for most cannabinoids (THC, 11OH-THC, THC-COOH, THCV-COOH, CBC, CBG, and CBD), there was only a slight further decline approximately of an additional 5%-12% observed for the following period of 3 months. There are discrepancies among the long-term stability results reported by different laboratories, depending on the coagulant used and artificially enriched samples versus in vitro stability in study samples. 35, 50 Our results are in alignment with results published by Grauwiler et al, 35 who also prepared the samples (urine and plasma) by enrichment with cannabinoid stock solutions. The instability during long-term storage, which has not been shown for accelerated short-term stability experiments, could not be explained by enzymatic processes but rather by binding to container surfaces or irreversible binding to plasma components or proteins resulting in a decreased recovery. Also, QC samples used for stability assessment in this study were enriched with cannabinoids dissolved in methanol. These samples contain methanol from the working solutions after enrichment, which could impact long-term stability results.
Scheidweiler et al 50 used heparin plasma from study subjects after cannabis administration and showed stability for up to 6 months. The difference to the present study, which used spiked blank EDTA plasma, is that the clinical samples did not contain organic solvents as used for the cannabinoid enrichment of blank samples. Based on this comparison, it can be speculated that organic solvents may have negatively impacted our long-term stability studies. However, relying on patient samples after cannabis consumption would not have been feasible here, as there is no Cannabis plant that contains all cannabinoids included in the present assay at sufficient concentrations for stability assessment.
CONCLUSION
In summary, our analysis of 352 plasma and 93 urine samples collected during clinical and observational studies provided first proof of concept of the present validated, highthroughput, sensitive, and specific LC-MS/MS assay for the quantification of 11 cannabinoids, suggesting that this assay is useful for clinical monitoring and cannabis research studies.
